Galectin-3 as a Novel Biomarker of Cardiovascular Disease

Abstract

Get full access to this article

View all access options for this article.

References

Kokturk

Püşüroğlu

Somuncu

, et al. Short and long-term prognostic significance of Galectin-3 in patients with ST-Elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2023;74:889-896.

Asleh

Enriquez-Sarano

Jaffe

, et al. Galectin-3 levels and outcomes after myocardial infarction: A population-based study. J Am Coll Cardiol. 2019;73:2286-2295.

Guo

Huang

, et al. Association between serum Galectin-3 levels and coronary stenosis severity in patients with coronary artery disease. Front Cardiovasc Med. 2022;9:818162.

Tymińska

Kapłon-Cieślicka

Ozierański

, et al. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Pol Arch Intern Med. 2019;129:770-780.

Suthahar

Meijers

Silljé

HHW

Liu

de Boer

. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: An update. Theranostics. 2018;8:593-609.

Ruifrok

WPT

Meissner

, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107-117.

Henderson

Mackinnon

Farnworth

, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006;103:5060-5065.

Fontana Estevez

Betazza

Miksztowicz

, et al. Genetic Deletion of Galectin-3 Exacerbates Age-Related Myocardial Hypertrophy and Fibrosis in Mice. Cell Physiol Biochem. 2022;56:353-366.

Gonzalez

Cassaglia

Noli Truant

, et al. Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. Int J Cardiol. 2014;176:1423-1425.